Construction and Validation of a Convenient Clinical Nomogram to Predict the Risk of Brain Metastasis in Renal Cell Carcinoma Patients

Abstract

Brain metastasis (BM) is a typical type of metastasis in renal cell carcinoma (RCC) patients. The early detection of BM is likely a crucial step for RCC patients to receive appropriate treatment and prolong their overall survival. The aim of this study was to identify the independent predictors of BM and construct a nomogram to predict the risk of BM. Demographic and clinicopathological data were obtained from the Surveillance, Epidemiology, and End Results (SEER) database for RCC patients between 2010 and 2015. Univariate and multivariate logistic regression analyses were performed to identify the independent risk factors, and then, a visual nomogram was constructed. Multiple parameters were used to evaluate the discrimination and clinical value. We finally included 42577 RCC patients. Multivariate logistic regression analysis showed that histological type, tumor size, bone metastatic status, and lung metastatic status were independent BM-associated risk factors for RCC. We developed a nomogram to predict the risk of BM in patients with RCC, which showed favorable calibration with a $C$-index of 0.924 (0.903-0.945) in the training cohort and 0.911 (0.871-0.952) in the validation cohort. The calibration curves and decision curve analysis (DCA) also demonstrated the reliability and accuracy of the clinical prediction model. The nomogram was shown to be a practical, precise, and personalized clinical tool for identifying the RCC patients with a high risk of BM, which not only will contribute to the more reasonable allocation of medical resources but will also enable a further improvements in the prognosis and quality of life of RCC patients.

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Renal cell carcinoma (RCC) is a common malignancy of the genitourinary system [1], with over 400,000 new cases and 17,000 RCC-associated mortalities in 2018 worldwide [2]. Approximately one-quarter of patients with RCC have metastatic disease at the time of diagnosis, and another 35% of them will develop distant metastases (DMs) during the process of tumor progression [3, 4]. Brain metastasis (BM) is a typical type of metastasis in RCC patients. In a study conducted by Bianchi et al., it was shown that the rate of BM ranged from 2% to 16% in metastatic RCC (mRCC) [5]. Although noticeable progress has been made in tumor treatment during the last several decades, renal cell carcinoma with brain metastasis (RCCBM) exhibits a limited response to current anticancer treatment methods [6–8]. BM is still thought to be closely related to mortality for patients with advanced-stage RCC [9]. The median overall survival of RCC patients with BM has been described as only 5-8 months [10, 11]. Thus, RCCBM is considered a significant issue in RCC studies.

The evaluation of BM in RCC may help improve clinical outcome and perhaps contribute to decreasing the potential risks of aggressive multimodality treatment required for advanced-stage cancer. Verma and his colleagues found that the use of tyrosine kinase inhibitors (TKIs) influenced the natural disease course and prognosis of RCC by preventing the development of BM [12]. Thus, the improved understanding and surveillance of BM will be beneficial for improving long-term prognosis for RCC patients. Some exploratory-stage predictors have been reported to evaluate the risks of BM in RCC. A retrospective study on 52 RCCBM patients revealed that smoking cigarettes and lung metastases were highly associated with the RCCBM [13]. However, no studies have focused on the development of an ideal predictive model for predicting the risk of BM in RCC, which means that the probability of BM cannot be quantified. In other words, the performance of BM-related factors in the prospective prediction of BM in RCC patients is still unknown. Due to the rarity of BM in RCC, obtaining adequate cases from our clinical practice to conduct the current study was extremely difficult. Thus, we used the Surveillance, Epidemiology, and End Results (SEER) database, a commonly used tool to study rare tumors, which provides data from 18 cancer registries and includes approximately 30% of the United States population. Therefore, the purpose of this study was to establish and validate a clinical prediction model to quantifying the risk of BM for RCC patients based on the SEER database. This study will help to promote personalized treatment and medical decision-making for patients with RCC.

2. Materials and Methods

2.1. Study Population Selection

The study population was derived from the SEER database, and the data were downloaded with SEER$\ast$Stat software version 8.3.6. The SEER program is an open access database which sponsored by the National Cancer Institute that contains demographic and clinicopathological information on cancer incidence and survival from 18 population-based cancer registries. The inclusion criteria were as follows: (1) patients with a histological diagnosis of RCC from 2010 to 2015 (histologic codes: 8310/3, 8313/3, 8260/3, 8317/3, 8270/3, and 8319/3); (2) RCC was the first and only primary cancer; patients with important clinical information on age, race, sex, histological type, histological grade, laterality, T stage, N stage, tumor size, insurance status, marital status, and distant metastatic status (brain, lung, bone, and liver) were unknown and excluded from this study. Finally, a total of 42577 RCC patients were identified to evaluate risk factors for the development of BM in patients with RCC and construct a diagnostic nomogram. In addition, this study was exempt from a medical ethics review and did not require informed consent because the data extracted from the SEER database were anonymized and deidentified prior to release. Figure 1 shows the process of patients’ selection procedure in this study.

[figure omitted; refer to PDF]

[figures omitted; refer to PDF]

[figures omitted; refer to PDF]

[figures omitted; refer to PDF]

[figures omitted; refer to PDF]

4. Discussion

In recent decades, considerable advances in tumor therapy have significantly improved the overall survival of mRCC patients [14, 15]. BM in RCC is still an important topic in the field of kidney malignancy research. Although the occurrence of BM is relatively low, it was reported that the presence of BM signified a worse prognosis compared with the lung or bone metastases [16]. A recent retrospective study suggested that the median overall survival of RCCBM patients was only 8.2 months [17]. However, the early detection of BM is likely a crucial step for RCC patients to receive appropriate treatment and prolong their overall survival. Nevertheless, brain imaging is not routinely recommended for all RCC patients based on surveillance guidelines from the American Urologic Association, European Association of Urology, and National Comprehensive Cancer Network, unless clinical or laboratory evidence indicates a high risk of BM for individual patients [18–20].

It therefore seems significant for clinical decision-making and personalized management to explore BM-related predictors in RCC patients and identify RCC patients with a high risk of BM. A conventional study reported that tumor size and age were risk factors for BM in RCC [21]. However, to date, a convenient predictive model for predicting BM in RCC has not been developed, which means that the personal risk of BM cannot be accurately estimated by combining all independent risk factors for BM. Nomograms are an easy-to-understand and multivariate visualization model to predict and quantify the incidence of a specific clinical outcome for individual patients and are widely applied in various malignancies [22–24]. Each independent risk factor included in the model was given a weighted point value to represent its effect on BM in RCC. This tool could be used to provide a reference for scientific and rational clinical decisions and promote the development of precision cancer medicine.

In our study, the analysis based on the SEER database from 2010 to 2015 indicated that histological type, tumor size, bone metastatic status, and lung metastatic status were independent risk factors for BM in RCC. There might be a relationship between histological grade, race, T stage, N stage, liver metastasis status, and BM, while these variables did not show a statistically significant association with BM in the multivariate analysis. A visual nomogram was thus developed to predict the probability of BM in RCC. The established nomogram had high accuracy and sensitivity in terms of identifying BM in RCC, and its calibration curves also showed good concordance between predicted and observed BM probabilities. Clear cell RCC (ccRCC) patients with a tumor $\text{size}\ge 7\text{cm}$ and bone and lung metastasis have higher a risk of BM. Even though in the absence of concerning neurological symptoms, including headache, dizziness, and altered consciousness, targeted brain imaging should be performed for RCC patients with a high risk of BM during a clinical follow-up. Generally, biological characteristics of the tumor play a crucial role in disease progression and are thought to be closely correlated with metastasis formation [25]. In a previous study, tumor size was proven to be a significant factor in the progression of distant metastasis for RCC patients, and there was a linear positive correlation between tumor size and the metastatic rate [26]. This observation was also confirmed in our study. RCC patients with larger tumor diameters (>7 cm) showed a higher risk of BM in multivariate analysis. In a retrospective series focused on patients with metastatic RCC in the brain, Shuch et al. suggested that clear cell RCC appeared to be the predominant histological type that metastasized to the brain, and this type accounted for 92.7% of RCC patients with BM [27]. Suarez-Sarmiento et al. also found that clear cell RCC patients were prone to developing BM [28]. Our study also identified histological type as an independent BM-related risk factor for RCC patients, which was similar to previous observations. Furthermore, in 2011, Verma et al. reported that lung metastasis was associated with a significantly high risk of developing BM in RCC patients [12]. Among 44 RCCBM patients, almost 90% had lung metastasis at diagnosis, and only 2.5% of RCC patients without lung metastasis ultimately developed BM. Therefore, it is worth investigating whether other extracranial metastases promote the development of BM in a synergistic manner. Our study also found that lung and bone metastatic status were the independent risk factors for BM in RCC patients. Although we found that RCC patients with lung or bone metastasis face a higher risk of BM, the complex mechanism remains unclear.

To the best of our knowledge, this is the first report on the construction of a practical nomogram for accurately predicting the probability of BM in RCC. Our comprehensive nomogram could be used as a supportive graphic tool to identify RCC patients with a considerably high propensity for BM, which not only will contribute to the more reasonable allocation of medical resources but will also enable further improvements in the prognosis and quality of life of RCC patients. The established nomogram demonstrated high accuracy and sensitivity for identifying BM in RCC, and its calibration curves also showed good concordance between predicted and observed BM probabilities. Even more notably, the ROC analysis in our study confirmed that the discriminative power of the nomogram was better than that of any the independent risk factors, again illustrating the significance of a comprehensive predictive model (Figure 5). In addition, the identified independent BM-related factors in our study are easily accessible in the daily clinic.

However, there were also some limitations of this study that should be mentioned. First, some selection bias was inevitable due to the retrospective design of our study. Second, we could not evaluate patients who developed BM after being diagnosed with RCC and during the disease course because detailed follow-up data about BM were not recorded in the SEER database. Third, the nomogram provided a relative reference for clinical doctors. In addition to the independent variables included in the nomogram, several other potentially significant details were missing in the current study, such as some laboratory data, molecular biological information of tumors, and clinical symptoms. Fourth, although it highlighted several of the most common metastatic sites of RCC patients, it did not provide data regarding other important types of metastases, such as adrenal metastases. The severity of metastases to other organs could not be obtained from the SEER database.

5. Conclusion

The present study identified tumor size, histological type, bone metastatic status, and lung metastatic status as independent risk factors of BM in RCC patients. These independent BM-associated risk factors were integrated to build a diagnostic nomogram to identify RCC patients with a high risk of BM.

Authors’ Contributions

Yuexin Tong and Youxin Song conceived and designed the study. Yuexin Tong, Changxing Chi, and Zhangheng Huang collected the clinical data and literature review. Chuan Hu conducted the statistical analysis and generated the figures and tables. Yuexin Tong wrote the manuscript. Yuexin Tong and Youxin Song revised the manuscript. Youxin Song supervised the research. All authors critically read the manuscript to improve intellectual content. All authors read and approved the final manuscript. Yuexin Tong, Zhangheng Huang, and Chuan Hu contributed equally to this work.

Acknowledgments

We are thankful for the contribution of the SEER database and the 18 registries supplying cancer research information and thank all colleagues and staff involved in the study for their contributions.

Glossary

Abbreviations

RCC:Renal cell carcinoma

BM:Brain metastasis

mRCC:Metastatic renal cell carcinoma

SEER:Surveillance, Epidemiology, and End Results

ROC:Receiver operating characteristic

DCA:Decision curve analysis

AUC:Area under the curve.

References

[1] R. L. Siegel, K. D. Miller, A. Jemal, "Cancer statistics, 2020," CA: A Cancer Journal for Clinicians, vol. 70 no. 1,DOI: 10.3322/caac.21590, 2020.

[2] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, A. Jemal, "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," CA: A Cancer Journal for Clinicians, vol. 68 no. 6, pp. 394-424, DOI: 10.3322/caac.21492, 2018.

[3] A. Rodriguez-Vida, T. E. Hutson, J. Bellmunt, M. H. Strijbos, "New treatment options for metastatic renal cell carcinoma," ESMO Open, vol. 2 no. 2, article e000185,DOI: 10.1136/esmoopen-2017-000185, 2017.

[4] K. Gupta, J. D. Miller, J. Z. Li, M. W. Russell, C. Charbonneau, "Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review," Cancer Treatment Reviews, vol. 34 no. 3, pp. 193-205, DOI: 10.1016/j.ctrv.2007.12.001, 2008.

[5] M. Bianchi, M. Sun, C. Jeldres, S. F. Shariat, Q. D. Trinh, A. Briganti, Z. Tian, J. Schmitges, M. Graefen, P. Perrotte, M. Menon, F. Montorsi, P. I. Karakiewicz, "Distribution of metastatic sites in renal cell carcinoma: a population-based analysis," Annals of Oncology, vol. 23 no. 4, pp. 973-980, DOI: 10.1093/annonc/mdr362, 2012.

[6] J. Hu, W. Guan, P. Liu, J. Dai, K. Tang, H. Xiao, Y. Qian, A. C. Sharrow, Z. Ye, L. Wu, H. Xu, "Endoglin is essential for the maintenance of self-renewal and chemoresistance in renal cancer stem cells," Stem Cell Reports, vol. 9 no. 2, pp. 464-477, DOI: 10.1016/j.stemcr.2017.07.009, 2017.

[7] A. Parmar, B. Sander, G. A. Bjarnason, K. K. W. Chan, "Systemic therapy in metastatic renal cell carcinoma: emerging challenges in therapeutic choice," Critical Reviews in Oncology/Hematology, vol. 152, article 102971,DOI: 10.1016/j.critrevonc.2020.102971, 2020.

[8] M. Tenold, P. Ravi, M. Kumar, A. Bowman, H. Hammers, T. K. Choueiri, Lara PN Jr, "Current approaches to the treatment of advanced or metastatic renal cell carcinoma," American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, vol. 40,DOI: 10.1200/EDBK_279881, 2020.

[9] R. Soffietti, P. Cornu, J. Y. Delattre, R. Grant, F. Graus, W. Grisold, J. Heimans, J. Hildebrand, P. Hoskin, M. Kalljo, P. Krauseneck, C. Marosi, T. Siegal, C. Vecht, "EFNS guidelines on diagnosis and treatment of brain metastases: report of an EFNS task force," European Journal of Neurology, vol. 13 no. 7, pp. 674-681, DOI: 10.1111/j.1468-1331.2006.01506.x, 2006.

[10] I. A. Bowman, A. Bent, T. le, A. Christie, Z. Wardak, Y. Arriaga, K. Courtney, H. Hammers, S. Barnett, B. Mickey, T. Patel, T. Whitworth, S. Stojadinovic, R. Hannan, L. Nedzi, R. Timmerman, J. Brugarolas, "Improved survival outcomes for kidney cancer patients with brain metastases," Clinical Genitourinary Cancer, vol. 17 no. 2, pp. e263-e272, DOI: 10.1016/j.clgc.2018.11.007, 2019.

[11] W. Zhuang, Y. Li, P. Chen, J. Wang, W. Liu, J. Chen, "Do renal cell carcinoma patients with brain metastases still need nephrectomy?," International Urology and Nephrology, vol. 51 no. 6, pp. 941-949, DOI: 10.1007/s11255-019-02139-9, 2019.

[12] J. Verma, E. Jonasch, P. Allen, N. Tannir, A. Mahajan, "Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma," Cancer, vol. 117 no. 21, pp. 4958-4965, DOI: 10.1002/cncr.26138, 2011.

[13] M. Hanzly, D. Abbotoy, T. Creighton, G. Diorio, D. Mehedint, C. Murekeyisoni, K. Attwood, E. Kauffman, A. J. Fabiano, T. Schwaab, "Early identification of asymptomatic brain metastases from renal cell carcinoma," Clinical & Experimental Metastasis, vol. 32 no. 8, pp. 783-788, DOI: 10.1007/s10585-015-9748-8, 2015.

[14] A. Schmidt, A. Azad, J. Goh, C. Harris, A. M. Joshua, A. Weickhardt, L. Krieger, "Treatment selection for first-line metastatic renal cell carcinoma in Australia: impact of new therapy options," Asia-Pacific Journal of Clinical Oncology, vol. 15,DOI: 10.1111/ajco.13289, 2019.

[15] E. Jonasch, "NCCN Guidelines updates: management of metastatic kidney cancer," Journal of the National Comprehensive Cancer Network, vol. 17 no. 5.5, pp. 587-589, DOI: 10.6004/jnccn.2019.5008, 2019.

[16] T. Chandrasekar, Z. Klaassen, H. Goldberg, G. S. Kulkarni, R. J. Hamilton, N. E. Fleshner, "Metastatic renal cell carcinoma: patterns and predictors of metastases-A contemporary population-based series," Urologic Oncology: Seminars and Original Investigations, vol. 35 no. 11, pp. 661.e7-661.e14, DOI: 10.1016/j.urolonc.2017.06.060, 2017.

[17] N. Takeshita, M. Otsuka, T. Kamasako, T. Somoto, T. Uemura, T. Shinozaki, M. Kobayashi, H. Kawana, M. Itami, T. Iuchi, A. Komaru, S. Fukasawa, "Prognostic factors and survival in Japanese patients with brain metastasis from renal cell cancer," International Journal of Clinical Oncology, vol. 24 no. 10, pp. 1231-1237, DOI: 10.1007/s10147-019-01474-2, 2019.

[18] B. Ljungberg, K. Bensalah, S. Canfield, S. Dabestani, F. Hofmann, M. Hora, M. A. Kuczyk, T. Lam, L. Marconi, A. S. Merseburger, P. Mulders, T. Powles, M. Staehler, A. Volpe, A. Bex, "EAU guidelines on renal cell carcinoma: 2014 update," European Urology, vol. 67 no. 5, pp. 913-924, DOI: 10.1016/j.eururo.2015.01.005, 2015.

[19] S. M. Donat, M. Diaz, J. T. Bishoff, J. A. Coleman, P. Dahm, I. H. Derweesh, S. D. Herrell, S. Hilton, E. Jonasch, D. W. Lin, V. E. Reuter, S. S. Chang, "Follow-up for clinically localized renal neoplasms: AUA Guideline," The Journal of Urology, vol. 190 no. 2, pp. 407-416, DOI: 10.1016/j.juro.2013.04.121, 2013.

[20] R. J. Motzer, E. Jonasch, N. Agarwal, C. Beard, S. Bhayani, G. B. Bolger, S. S. Chang, T. K. Choueiri, I. H. Derweesh, S. Gupta, S. L. Hancock, J. J. Kim, T. M. Kuzel, E. T. Lam, C. Lau, E. G. Levine, D. W. Lin, K. A. Margolin, M. D. Michaelson, T. Olencki, R. Pili, E. R. Plimack, E. N. Rampersaud, B. G. Redman, C. J. Ryan, J. Sheinfeld, K. Sircar, B. Somer, J. Wang, R. B. Wilder, M. A. Dwyer, R. Kumar, Natiomal compresensive cancer networks, "Kidney cancer, version 2.2014," Journal of the National Comprehensive Cancer Network: JNCCN, vol. 12 no. 2, pp. 175-182, DOI: 10.6004/jnccn.2014.0018, 2014.

[21] Z. B. Ke, S. H. Chen, Y. H. Chen, Y. P. Wu, F. Lin, X. Y. Xue, Q. S. Zheng, N. Xu, Y. Wei, "Risk factors for brain metastases in patients with renal cell carcinoma," BioMed Research International, vol. 2020,DOI: 10.1155/2020/6836234, 2020.

[22] W. Gui, W. Zhu, W. Lu, C. Shang, F. Zheng, X. Lin, H. Li, "Development and validation of a prognostic nomogram to predict overall survival and cancer-specific survival for patients with anaplastic thyroid carcinoma," PeerJ, vol. 8, article e9173,DOI: 10.7717/peerj.9173, 2020.

[23] K. Chen, X. Deng, Z. Yang, D. Yu, X. Zhang, J. Zhang, D. Xie, Z. He, D. Cheng, "Survival nomogram for patients with metastatic siewert type II adenocarcinoma of the esophagogastric junction: a population-based study," Expert Review of Gastroenterology & Hepatology, vol. 14 no. 8, pp. 757-764, DOI: 10.1080/17474124.2020.1784726, 2020.

[24] X. Shang, H. Yu, J. Lin, Z. Li, C. Zhao, J. Sun, H. Wang, "A novel nomogram including AJCC stages could better predict survival for NSCLC patients who underwent surgery: a large population-based study," Journal of Oncology, vol. 2020,DOI: 10.1155/2020/7863984, 2020.

[25] A. Pecoraro, C. Palumbo, S. Knipper, G. Rosiello, S. Luzzago, Z. Tian, S. F. Shariat, F. Saad, L. Lavallée, A. Briganti, A. Kapoor, C. Fiori, F. Porpiglia, P. I. Karakiewicz, "Histologic subtype, tumor grade, tumor size, and race can accurately predict the probability of synchronous metastases in T2 renal cell carcinoma," Clinical Genitourinary Cancer, vol. 18 no. 5, pp. e610-e618, DOI: 10.1016/j.clgc.2020.02.001, 2020.

[26] H. Lee, J. K. Lee, K. Kim, C. Kwak, H. H. Kim, S. S. Byun, S. E. Lee, S. K. Hong, "Risk of metastasis for T1a renal cell carcinoma," World Journal of Urology, vol. 34 no. 4, pp. 553-559, DOI: 10.1007/s00345-015-1659-4, 2016.

[27] B. Shuch, J. C. la Rochelle, T. Klatte, S. B. Riggs, W. Liu, F. F. Kabbinavar, A. J. Pantuck, A. S. Belldegrun, "Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival," Cancer, vol. 113 no. 7, pp. 1641-1648, DOI: 10.1002/cncr.23769, 2008.

[28] A. Suarez-Sarmiento, K. A. Nguyen, J. S. Syed, A. Nolte, K. Ghabili, M. Cheng, S. Liu, V. Chiang, H. Kluger, M. Hurwitz, B. Shuch, "Brain metastasis from renal-cell carcinoma: an institutional study," Clinical Genitourinary Cancer, vol. 17 no. 6, pp. e1163-e1170, DOI: 10.1016/j.clgc.2019.08.006, 2019.